Dacinostat
- Catalog NO.:A825135
- CAS No. : 404951-53-7
- Molecular Formula:C22H25N3O3
- Molecular Weight: 379.45
Note*
1. Please click the to confirm the discount and stock quantity.
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Bulk Inquiry
1. Please click the to confirm the discount and stock quantity.
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Quality Control&SDS
SDS
Product Details
CAS Number | 404951-53-7 | Appearance | Off-white powder |
Catalog Number | A825135 | MDL Number | MFCD09970778 |
Molecular Formula | C22H25N3O3 | Molecular Weight | 379.45 |
Boiling Point | Melting Point | ||
Flash Point | Density | ||
Synonyms | NVP LAQ824;(2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide;(E)-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enehydroxamic acid | ||
Storage Condition | Store in a tightly closed container,in a cool and dry place |
Safety
GHS Pictogram | |||
Signal Word | Warning | UN Number | |
Hazard Statements | H302-H317 | Class | |
Precautionary Statements | P280 | Packing Group |
Description
Dacinostat, also known as LAQ824, is a hydroxamate histone deacetylase inhibitor with potential anticancer activity. LAQ824 sensitized nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation. LAQ824 reduced clonogenic survival of the H23 and H460 cell lines five-fold compared with controls and four-fold compared with either agent alone (P<0.001). In phase I trials, LAQ824 was well tolerated at doses that induced accumulation of histone acetylation, with higher doses inducing changes consistent with HSP90 inhibition. |